Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of ...
21d
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, ...
Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results